Evidence map›Paper›PMID 39379424›Full record

ArticleScientific reports2024

MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2D

Hitoshi Toyoda, Atsuo Kuramasu, Masahiro Hosonuma, Masakazu Murayama, Yoichiro Narikawa, Junya Isobe, Yuta Baba, Kohei Tajima, Eiji Funayama, Midori Shida and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Hitoshi ToyodaDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Atsuo KuramasuDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Masahiro HosonumaDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Masakazu MurayamaDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Yoichiro NarikawaDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Junya IsobeDepartment of Hospital Pharmaceutics, Showa University School of Pharmacy, Tokyo, 142-8555, Japan.
Yuta BabaDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Kohei TajimaDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Eiji FunayamaDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Midori ShidaDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Yuki MaruyamaDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Aya SasakiDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan.
Yuya HirasawaDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Toshiaki TsuruiDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Hirotsugu AriizumiDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Tomoyuki IshiguroDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Risako SuzukiDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Sei KobayashiDepartment of Otorhinolaryngology, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Atsushi HoriikeDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Noriko HidaDivision of Clinical Pharmacology, Department of Pharmacology, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Takehiko SambeDivision of Clinical Research and Development, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, 142-8555, Japan.
Koji NobePharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.
Satoshi WadaDepartment of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, 157-8577, Japan.
Hitome KobayashiDepartment of Otorhinolaryngology, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Mayumi TsujiPharmacological Research Center, Showa University, Tokyo, 142-8555, Japan.
Shinichi KobayashiClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, 157-8577, Japan.
Takuya TsunodaDivision of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Yoshifumi KudoDepartment of Orthopedic Surgery, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Yuji KiuchiDepartment of Pharmacology, Showa University School of Medicine, Tokyo, 142-8555, Japan.
Kiyoshi YoshimuraDepartment of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, 6-11-11 Kita-karasuyama, Setagaya-ku, Tokyo, 157-8577, Japan. kyoshim1@med.showa-u.ac.jp.

Funding

Japan Society for the Promotion of Science 21K08785
6 · The paper itself

Abstract

Natural killer group 2 member D ligands (NKG2DLs) are expressed as stress response proteins in cancer cells. NKG2DLs induce immune cell activation or tumor escape responses, depending on their expression. Human pancreatic cancer cells, PANC-1, express membrane MHC class I polypeptide-related sequence A/B (mMICA/B), whereas soluble MICB (sMICB) is detected in the culture supernatant. We hypothesized that sMICB saturates NKG2D in NKG2D

Indexed as

Histocompatibility Antigens Class ILymphocyte ActivationNK Cell Lectin-Like Receptor Subfamily KPancreatic NeoplasmsT-LymphocytesADAM17 ProteinAnimalsCell Line, TumorHumansMiceTumor EscapeADAM17 ProteinHistocompatibility Antigens Class IKLRK1 protein, humanMICB antigenNK Cell Lectin-Like Receptor Subfamily KADAMImmunityMICBNKG2DNKG2DLPancreatic tumorT cell

Identifiers

PMID39379424
PMCPMC11461622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.